Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Insider Sells $107,161.35 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Dianne C. Whitfield sold 2,315 shares of Tarsus Pharmaceuticals stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $107,161.35. Following the completion of the sale, the insider now owns 50,751 shares in the company, valued at approximately $2,349,263.79. This represents a 4.36 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ:TARS opened at $49.97 on Friday. The company has a market capitalization of $1.92 billion, a price-to-earnings ratio of -13.12 and a beta of 1.05. Tarsus Pharmaceuticals, Inc. has a 12 month low of $20.08 and a 12 month high of $57.28. The firm’s 50-day moving average is $48.48 and its 200 day moving average is $45.35. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.08. The company had revenue of $66.41 million for the quarter, compared to the consensus estimate of $58.80 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. Research analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TARS. Oppenheimer lifted their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. Barclays reduced their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Jefferies Financial Group boosted their target price on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. Guggenheim restated a “buy” rating and issued a $78.00 target price (up from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. Finally, HC Wainwright restated a “buy” rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $63.67.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. Summit Investment Advisors Inc. grew its holdings in Tarsus Pharmaceuticals by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company’s stock valued at $213,000 after purchasing an additional 244 shares during the last quarter. Sherbrooke Park Advisers LLC boosted its position in Tarsus Pharmaceuticals by 7.2% in the 4th quarter. Sherbrooke Park Advisers LLC now owns 6,571 shares of the company’s stock valued at $364,000 after buying an additional 443 shares during the period. Crowley Wealth Management Inc. purchased a new stake in Tarsus Pharmaceuticals in the 4th quarter valued at about $25,000. Bank of New York Mellon Corp boosted its position in Tarsus Pharmaceuticals by 0.5% in the 4th quarter. Bank of New York Mellon Corp now owns 101,928 shares of the company’s stock valued at $5,644,000 after buying an additional 498 shares during the period. Finally, Swiss National Bank boosted its position in Tarsus Pharmaceuticals by 1.2% in the 4th quarter. Swiss National Bank now owns 52,333 shares of the company’s stock valued at $2,898,000 after buying an additional 600 shares during the period. 90.01% of the stock is currently owned by institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.